CAR-T cell therapy
Facts for Prelims (FFP) Source: The Print Context: India’s Drug Controller General (DCGI) has granted market authorization for CAR-T (Chimeric Antigen Receptor-T) cell therapy developed by ImmunoACT, a spin-off company from IIT-Bombay. This ground-breaking treatment, known as NexCAR19, is now approved for use in cases of relapsed-refractory B-cell lymphoma and leukaemia. The therapy’s …








